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Abstract 
Background: Poly(ADP‑ribose) polymerase (PARP) inhibitors have entered the clinics for their promising anticancer 
effect as adjuvant in chemo‑ and radiotherapy and as single agent on BRCA‑mutated tumours. Poly(ADP‑ribose) gly‑
cohydrolase (PARG) deficiency was also shown to potentiate the cytotoxicity of genotoxic agents and irradiation. The 
aim of this study is to investigate the effect of PARG deficiency on BRCA1‑ and/or PTEN‑deficient tumour cells.
Methods: Since no PARG inhibitors are available for in vivo studies, PARG was depleted by siRNA in several cancer cell 
lines, proficient or deficient for BRCA1 and/or PTEN. The impact on cell survival was evaluated by colony formation 
assay and short‑term viability assays. The effect of simultaneous PARG and BRCA1 depletion on homologous recombi‑
nation (HR) efficacy was evaluated by immunodetection of RAD51 foci and using an in vivo HR assay.
Results: The BRCA1‑deficient cell lines MDA‑MB‑436, HCC1937 and UWB1.289 showed mild sensitivity to PARG 
depletion, whereas no sensitivity was observed for the BRCA1‑proficient MDA‑MB‑231, MDA‑MB‑468, MCF10A and 
U2OS cell lines. However, the BRCA1‑reconstituted UWB1.289 cell lines was similarly sensitive to PARG depletion than 
the BRCA1‑deficient UWB1.289, and the simultaneous depletion of PARG and BRCA1 and/or PTEN in MDA‑MB‑231 or 
U2OS cells was not more cytotoxic than depletion of BRCA1 or PTEN only.
Conclusions: Some tumour cells displayed slight sensitivity to PARG deficiency, but this sensitivity could not be cor‑
related to BRCA1‑ or PTEN‑deficiency. Therefore, PARG depletion cannot be considered as a strategy to kill tumours 
cells mutated in BRCA1 or PTEN.
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Background
Poly(ADP-ribosyl)ation (PARylation) is a post-transla-
tional modification of proteins involved in many bio-
logical processes, among them the surveillance and 
maintenance of genome integrity [1, 2]. In response 
to DNA strand breaks, PARP-1, the founding member 
of the poly(ADP-ribose) polymerases (PARP) family, 
immediately and actively transfers single or successive 
ADP-ribose units from NAD+ to acceptor proteins to 
synthesize poly(ADP-ribose) (PAR) at the damaged site, 
to signal the lesion and to efficiently and rapidly recruit 
chromatin modulators and DNA repair factors. PARyla-
tion is a transient modification, its kinetics and intensity 
is tightly controlled through the prompt and efficient 
degradation of PAR by the glycohydrolase activity of 
poly(ADP-ribose) glycohydrolase (PARG). PARG exists as 
multiple isoforms localized to different cellular compart-
ment [3, 4]. In mice, invalidation of all PARG isoforms is 
embryonic lethal [5], whereas hypomorphic mutant mice 
or embryonic stem cells are viable but display increased 
sensitivity to ionizing radiation and alkylating agents [6, 
7]. We and others have shown that efficient depletion 
of all PARG isoforms in cellular models by RNA silenc-
ing increased cell death upon genotoxic stress, a con-
sequence of perturbed repair of damaged bases, single 
and double strand breaks and collapsed replication forks 
[8–11]. Therefore, both synthesis and degradation of PAR 
require tight regulation for competent repair [1, 2]. These 
results define PARG, like PARP-1, as a new candidate tar-
get to potentiate chemo- and radiotherapy [8, 12, 13].
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That PARP inhibition prejudices efficacy of break repair 
has been exploited as anticancer strategies to potentiate 
the cytotoxicity of anticancer drugs [14, 15]. Numerous 
phase I to III clinical trials based on this approach are 
in progress [14] (https://www.clinicaltrials.gov/). PARP 
inhibition has also proved to be exquisitely efficient to kill 
tumour cells deficient in double strand break repair by 
homologous recombination (HR), such as cells mutated 
for the breast cancer early onset (BRCA) genes BRCA1 
or BRCA2 [16, 17]. The proposed explanation for this 
synthetic lethality between PARP and BRCA is that sin-
gle strand breaks that arise spontaneously in cells are not 
efficiently repaired upon PARP inhibition, are thus con-
verted during replication to double strand breaks that 
cannot be repaired in BRCA deficient cells, leading to cell 
death. The capacity of PARP inhibitor to trap the inhib-
ited PARP-1 onto DNA breaks has been shown to be crit-
ical for the cytotoxic effect [18, 19]. The PARP inhibitor 
olaparib has just been approved for maintenance treat-
ment in advanced ovarian cancers with germline BRCA 
mutation and several phase III clinical trials are in pro-
gress for the treatment of breast and ovarian cancers with 
BRCA mutations [20].
Whether PARG deficiency could also be cytotoxic 
to BRCA1/2 deficiency has not been extensively stud-
ied. Yet one study showed the increased killing effect 
of PARG depletion in BRCA2 deficient cells [21]. In the 
present study, we tackled the hypothesis of synthetic 
lethality between PARG and BRCA1. Since currently 
available PARG inhibitors are not satisfying so far, ques-
tioned either for their specificity or for their cell perme-
ability [22], we evaluated the impact of PARG depletion 
by siRNA on cell survival of several breast and ovarian 
cancer cell lines either proficient or deficient in BRCA1. 
The phosphatase and TENsin homolog (PTEN) is a 
tumour suppressor gene regulating the PI3K/AKT signal-
ling pathway [23]. Since synthetic lethality between PARP 
inhibition and PTEN has also been reported, proposed 
to result from the impairment of HR caused by PTEN 
deficiency [24–27], we also examined the effect of PARG 
depletion on survival of cells endowed with a PTEN 
deficiency.
Results
PARG deficiency is not synthetic lethal with BRCA1 
deficiency
In order to evaluate whether PARG depletion sensi-
tizes cells mutated in BRCA1 by synthetic lethality, we 
depleted PARG by siRNA in several breast cancer cell 
lines either wild type or mutated for BRCA1. We selected 
the BRCA1-wild type MDA-MB-231 and BRCA1-
mutated MDA-MB-436 cell lines and first verified that 
only the MDA-MB-436 cells were highly sensitive to 
PARP inhibition in clonogenic assays, as described previ-
ously [28–31]. As expected, increasing concentrations of 
the PARP inhibitor KU-0058948 was far more cytotoxic 
in MDA-MB-436 than in MDA-MB-231 (Fig.  1a). We 
next depleted PARG by transient siRNA transfection in 
these two cell lines and evaluated cell survival by clono-
genic assay. Two different siRNAs targeting PARG were 
used, from different providers, siPARG and siPARG5, 
with their respective non-targeting controls siCTL, and 
AllNeg. Efficient knockdown of PARG expression was 
observed by western blot for both siRNA in both cell 
lines, for at least 120  h post-transfection, and was even 
still effective at 168 h in MDA-MB-436 (Fig. 1b, c, lower 
panels). None of the siRNA targeting PARG had an 
impact on MDA-MB-231 clonogenic survival (Fig.  1b, 
left panel). Short-term survival assays similarly revealed 
no impact on cell number at 72 h post-siRNA transfec-
tion or on cell viability 144 h post-transfection, after re-
seeding of the cells (Fig. 1b, middle and right panels). This 
suggests that MDA-MB-231 cells are not particularly sen-
sitive to PARG depletion. Similarly, other BRCA1-wild 
(See figure on next page.) 
Fig. 1 The BRCA1‑deficient MDA‑MB‑436 and HCC1937 cells but not the BRCA‑proficient MDA‑MB‑231 and MCF10A cells are slightly sensitive to 
PARG depletion. a The MDA‑MB‑436 cell line shows increased sensitivity to PARP inhibition compared to the MDA‑MB‑231 cell line. Colony forma‑
tion assays were performed with indicated concentrations of PARP inhibitor KU0058948. Mean values of triplicates (± SD) from one representative 
of 5 independent experiments are shown. b The BRCA1‑proficient MDA‑MB‑231 cell line is not sensitive to PARG depletion. Left panels Clonogenic 
survival of MDA‑MB‑231 cells transfected with siCTL, siPARG, AllNeg or siPARG5. Results are from 6 (siCTL and siPARG) and 3 (AllNeg and siPARG5) 
independent experiments. Middle panels Percentage of viable cells relative to non‑targeting siRNA transfected cells 72 h post‑transfection, time 
point when cells are re‑plated for clonogenic or short‑term MTS assay. Results show mean values ± SD of 7 (siCTL and siPARG) and 5 (AllNeg and 
siPARG5) independent experiments. Right panels Cell viability measured by MTS assays 144 h post‑transfection. Results show the percentage of via‑
bility relative to cells transfected with non‑targeting siRNA from 3 independent experiments. Lower panels PARG depletion was verified by western 
blot at the time post‑siRNA transfection indicated. #: non‑specific band. c Clonogenic survival (left panels), cell counting at 72 h post‑siRNA transfec‑
tion (middle panels) and short‑term MTS assay at 144 h post‑siRNA transfection (right panels) were performed in MDA‑MB‑436 cell line as described 
in b. Number of experiments was 7 (siCTL and siPARG) and 3 (AllNeg and siPARG5) for clonogenic assays, 8 (siCTL and siPARG) and 4 (AllNeg and 
siPARG5) for cell counting at 72 h and 3 for MTS assay at 144 h post‑siRNA transfection. Lower panels PARG depletion was verified by western blot at 
the time post‑siRNA transfection indicated. d Clonogenic survival of MCF10A (left panel) and HCC1937 (right panel) cells transfected with siCTL and 
siPARG. Results are depicted as in a from 6 independent experiments. p: *** < 0.001; 0.001 < ** < 0.01; 0.01 < * < 0.05; 0.05 < ns, not significant
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type cell lines tested, such as the non-tumour MCF10A 
breast cell line (Fig. 1d), the lung fibroblastic MRC5 cell 
line (data not shown) and the U2OS osteosarcoma cell 
line (Fig.  3b) showed no particular sensitivity to PARG 
depletion.
In contrast, both PARG-targeting siRNA significantly 
affected clonogenic survival of the BRCA1-deficient 
MDA-MB-436 cell line (Fig. 1c, left panel). PARG deple-
tion had however no significant impact on cell num-
ber at 72  h post-siRNA transfection or on cell viability 
144  h post-transfection (Fig.  1c, middle and right pan-
els, respectively). We concluded that clonogenic assay is 
more sensitive to uncover an eventual impact of PARG 
depletion on cell survival that is rather weak, probably 
because in this technique, cells have to recover from 
plating in discriminating conditions caused by their 
extreme dilution. SiPARG and siPARG5 impacted clo-
nogenic survival of MDA-MB-436 cell line to similar 
extent, validating their specificity. The fact that another 
BRCA1-impaired cell line, HCC1937, also displayed mild 
sensitivity to siPARG (Fig. 1d) could be in favour of a pos-
sible synthetic lethality between PARG depletion and 
BRCA1 deficiency.
To examine this hypothesis, the sensitivity to PARG 
depletion of another cancer cell line genetically deficient 
for BRCA1 was compared to that of the corresponding 
BRCA1-reconstituted cell line. We selected the BRCA1-
deficient ovarian cancer cell line UWB1.289 and the 
corresponding UWB1.289 + BRCA1 that expresses func-
tional human BRCA1 (Fig.  2a, b) [32]. PARG depletion 
was controlled by western blot, and revealed to be very 
efficient for both siRNA targeting PARG at 72  h post-
transfection, until at least 120  h post-transfection. Effi-
cient PARG depletion was also supported by the strong 
PAR increase, spontaneously accumulating at similar 
levels in both PARG-depleted cell lines (Fig. 2c). Clono-
genic assays revealed that both PARG-targeting siRNA 
slightly but significantly decreased cell survival of both 
cell lines, regardless of their BRCA1 status (Fig. 2a, b, left 
panels). Here again, short-term assays were less informa-
tive, with no significant difference observed at 72 h post-
transfection for all siRNA and only a slight decrease of 
viability observed at 144 h, significant only for siPARG5 
in UWB1.289 and siPARG in UWB1.289 + BRCA1 cells 
(Fig. 2a, b, middle and left panels). Therefore, considering 
results obtained with the more robust clonogenic assay, 
synthetic lethality between PARG depletion and BRCA1 
deficiency was not supported in the UWB1.289 cells.
To clarify our observations, we simultaneously depleted 
PARG and BRCA1 by siRNA in the BRCA1-proficient 
MDA-MB-231 cells (Fig. 3a). Western blot analyses with 
anti-BRCA1 and anti-PARG antibodies confirmed the 
efficient silencing of both genes (Fig.  3a). Whereas the 
single BRCA1 depletion shows cytotoxicity, as previ-
ously reported [33], decreasing the clonogenic survival to 
57 ±  5  %, the simultaneous depletion of PARG did not 
significantly enhance cell mortality (Fig.  3a, left panel). 
Of note even the siBRCA1, that dramatically reduces clo-
nogenic survival when used alone or in combination with 
siPARG, had no effect on short-term survival, at 72 h or 
144  h post-transfection (Fig.  3a, middle and right pan-
els). This supports that cell plating at very low density is 
critical to uncover an altered survival capacity. Compara-
ble results were observed by clonogenic assay when the 
siRNA-mediated depletion of BRCA1 and/or PARG was 
performed in the BRCA1-proficient U2OS osteosarcoma 
cell line, with even a slight increase in clonogenic survival 
of cells simultaneously depleted for PARG and BRCA1 
compared to cells depleted for BRCA1 only (Fig.  3b). 
Taken together, these results further support the conclu-
sion of a lack of synthetic lethality between PARG and 
BRCA1.
To verify that the siRNA-mediated depletion of BRCA1 
was functionally effective, we examined its impact on 
HR-efficiency. To this end, we utilized the in  vivo HR 
assay based on the HR-inducible U2OS-DR-GFP cell 
(See figure on next page.) 
Fig. 2 The BRCA1‑mutated UWB1.289 cell line is not more sensitive to PARG depletion than the BRCA1‑reconstituted UWB1.289 + BRCA1 cell line. 
a Left panels Clonogenic survival of UWB1.289 cells transfected with siCTL, siPARG, AllNeg or siPARG5. Results are depicted as box plots showing 
distribution of data from 7 (siCTL and siPARG) and 4 (AllNeg and siPARG5) independent experiments. Middle panels Percentage of viable cells relative 
to non‑targeting siRNA transfected cells 72 h post‑siRNA transfection, time point when cells are re‑plated for clonogenic or short‑term MTS assay. 
Results show mean values ± SD of 11 (siCTL and siPARG) and 4 (AllNeg and siPARG5) independent experiments. Right panels Cell viability measured 
by MTS viability assays 144 h post‑transfection. Results show the percentage of viability relative to cells transfected with non‑targeting siRNA from 
3 independent experiments. Lower panels PARG depletion was verified by western blot at the time post‑siRNA transfection indicated. b Clonogenic 
survival (left panels), relative cell number at 72 h post‑siRNA transfection (middle panels) and short‑term MTS assay at 144 h post‑siRNA transfection 
(right panels) were performed in UWB1.289 + BRCA1 cell line exactly as described in a. Results are depicted as box plots showing distribution of data 
from 7 (siCTL and siPARG) and 4 (AllNeg and siPARG5) for clonogenic assays. Number of experiments was 11 (siCTL and siPARG) and 4 (AllNeg and 
siPARG5) for cell counting at 72 h and 3 for MTS assay at 144 h post‑siRNA transfection. Lower panels PARG depletion was verified by western blot at 
the time post‑siRNA transfection indicated. c. Spontaneous PAR accumulation is a consequence of efficient PARG depletion in UWB1.289 (UWB) and 
UWB1.289 + BRCA1 (UWB + BRCA1) cells. PAR, BRCA1, PARG and actin levels were analysed by western blot using the indicated antibodies. BRCA1 
specific signal is indicated by arrowheads. p: *** < 0.001; 0.001 < ** < 0.01; 0.01 < * < 0.05; 0.05 < ns, not significant
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line, containing a stably integrated DR-GFP reporter 
and expressing the mCherry-I-SceI-GR fusion protein 
[34]. Upon binding to triamcinolone acetonide (TA), 
the mCherry-I-SceI-GR translocates from cytoplasm to 
nucleus to cleave an I-SceI site present in one of the two 
integrated mutated GFP-sequences, generating a DSB. 
Reconstitution of GFP after I-SceI-dependent HR was 
monitored by flow cytometry in cells transfected with 
siRNA targeting PARG, BRCA1 or both (Fig.  4a, b). In 
agreement with our previous observations [11], siPARG 
alone slightly reduced HR compared to scramble siCTL 
(0.89 ±  0.06 %). In contrast, BRCA1 depletion dramati-
cally reduced HR efficiency (0.23 ± 0.05 %), as expected. 
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Fig. 3 Co‑depletion of PARG does not potentiate cytotoxicity by BRCA1 depletion. a Clonogenic survival (left panel) of MDA‑MB‑231 cells after 
single or combined siRNA‑mediated depletion of BRCA1 and PARG. Results are depicted as box plots showing distribution of data from 4 individual 
experiments. Middle panel Percentage of viable cells relative to siCTL‑transfected cells 72 h post‑transfection, time point when cells are re‑plated 
for clonogenic or short‑term MTS assay. Results show mean values ± SD of 7 independent experiments. Right panel Cell viability measured by MTS 
viability assays 144 h post‑transfection. Results show the percentage of viability relative to cells transfected with siCTL from 3 independent experi‑
ments. Lower panel PARG and BRCA1 depletions were verified by western blot at the times indicated. b Clonogenic survival (left panel) of U2OS cells 
after single or combined siRNA‑mediated depletion of BRCA1 and PARG. Results are depicted as box plots showing distribution of data from 4 indi‑
vidual experiments. Percentage of viable cells relative to siCTL‑transfected cells 72 h post‑transfection (right panel). Results show mean values ± SD 
of 5 independent experiments. PARG and BRCA1 depletions at 72 h were verified by western blot (middle panel). BRCA1 specific signal is indicated 
by arrowhead. p: *** < 0.001; 0.001 < ** < 0.01; 0.01 < * < 0.05; 0.05 < ns, not significant
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depletion, HR was similarly impaired (0.29  ±  0.11  %) 
than in the context of the sole BRCA1 depletion, sug-
gesting that BRCA1 is efficiently silenced, affecting HR 
regardless of the presence of PARG.
To further examine the consequence of PARG and/
or BRCA1 siRNA-mediated depletion on HR efficiency, 
we examined by immunofluorescence the appearance of 
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Fig. 4 The HR defect caused by BRCA1‑depletion is not further affected by PARG depletion. a and b The frequency of HR‑mediated repair events 
was analysed by flow cytometry in U2OS‑DR‑GFP‑mCherry‑I‑SceI‑GR cells after transfection with the indicated siRNA and induction of DSB 
formation by incubation with TA for 48 h. The percentage of Cherry‑ and GFP‑positive cells is indicated. In b, the values correspond to the ratio 
of GFP‑positive cells relative to cells transfected with scrambled siRNA (siCTL), as illustrated in a, and represent the mean ± SD of 7 independent 
experiments. c and d Defect of etoposide‑induced RAD51 foci formation in BRCA1‑depleted cells is not further affected by PARG depletion. Cells 
transfected with the indicated siRNA were incubated with 10 µM etoposide for 1 h, released into fresh medium for 2 h and processed for immu‑
nofluorescence using anti‑RAD51 and anti‑γH2AX antibodies. Representative immunofluorescence image are shown in c. In d, the box plot graph 
depicts the percentage of cells displaying RAD51 foci (more than 10 RAD51 foci per cell) from 5 independent experiments scoring >200 nuclei for 
each condition. p: 0.01 < * < 0.05; 0.05 < ns, not significant
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topoisomerase II inhibitor etoposide. Cells were treated 
with 10  µM etoposide for 1  h and released in complete 
fresh medium for additional 2 h (Fig. 4c, d), time chosen 
from kinetic experiment as the best moment to detect 
RAD51 foci in these conditions of treatment (data not 
shown). The presence of DSB was revealed by co-staining 
for γH2AX (Fig.  4c). We have reported previously that 
RAD51 foci formation was impaired in PARG-depleted 
cells in conditions of massive PAR production caused 
by prolonged replicative stress known to generate DSB 
[11]. Etoposide is a good inducer of DSB but a poor trig-
ger of PAR synthesis [35]. In agreement, only limited 
PAR synthesis was observed in etoposide-treated PARG-
depleted cells (data not shown) and no significant dif-
ference of RAD51 foci formation was detected between 
siCTL and siPARG cells (Fig.  4c, d). BRCA1 depletion 
dramatically impaired the formation of RAD51 foci, as 
expected, with only 9.4  ±  3.4  % cells with RAD51 foci 
compared to 30.8 ± 5.8 % in siCTL cells. In the context 
of simultaneous PARG and BRCA1 depletion, more cells 
showed RAD51 foci (16.2 ±  6.85  %) but this difference 
was not statistically significant compared to the condi-
tion of the sole BRCA1 depletion (p = 0.37). This result 
is in complete accordance with the results of the in vivo 
HR analysis described above, demonstrating that BRCA1 
deficiency affects HR and that simultaneous PARG deple-
tion has no impact on this HR defect.
PARG deficiency is not synthetic lethal with PTEN 
deficiency
In addition of being deficient in BRCA1, the MDA-
MB-436 and HCC1937 cells that display a slight sensi-
tivity to PARG depletion (Fig. 1b, d), are also deficient in 
PTEN, a tumour suppressor gene regulating the PI3K/
AKT signalling pathway [23]. Synthetic lethality between 
PARP inhibition and PTEN has been described for sev-
eral cancer cell lines and proposed to result from the 
impairment of HR caused by PTEN deficiency [24–27]. 
In glioblastoma cell lines, PARP inhibition exacerbated 
the PTEN-dependent down-regulation of RAD51 tran-
scriptional expression, thus impairing HR [25, 36]. How-
ever, other findings have not supported these results, 
showing no impact on RAD51 expression and foci for-
mation by PTEN deficiency, and only mild sensitivity of 
PTEN-deficient cells to PARP inhibition in primary pros-
tate cancer cell lines and xenografts [37]. Furthermore, 
a recent study showed that the concurrent loss of PTEN 
and BRCA1 rather counteracts the HR-repair deficiency, 
conferring PARP inhibitor resistance [38].
In order to challenge the hypothesis of synthetic 
lethality between PARG and PTEN, we depleted PARG 
by siRNA in the PTEN-mutated but BRCA1-wild 
type MDA-MB-468 cell line and evaluated clonogenic 
survival. PARG depletion had no impact on the viable 
cell number at 72  h after siRNA transfection of MDA-
MB-468 cells, and did not affect the clonogenic survival 
of MDA-MB-468 cells, inferring that PARG-deficiency is 
not synthetic lethal with a PTEN mutation (Fig.  5a). In 
order to assess whether the simultaneous deficiency in 
BRCA1 and PTEN was necessary to confer sensitivity to 
PARG depletion, we performed the triple depletion of 
PARG, BRCA1 and PTEN by siRNA in MDA-MB-231 
cells and compared it to the single BRCA1 depletion, and 
to BRCA1/PARG and BRCA1/PTEN double depletions 
(Fig. 5b). Cells transfected with siBRCA1 were used here 
as the reference, since single BRCA1 depletion already 
strongly affects clonogenic survival (Fig.  3 and [33]). 
Cell number, at the time of plating for clonogenic assay 
didn’t vary from that of siBRCA1-transfected cells for any 
combination of siRNA used (Fig. 5b, right panel). Clono-
genic assay revealed that PARG silencing was not cyto-
toxic to BRCA1/PTEN-depleted cells and rather slightly 
increased their clonogenic survival (Fig.  5b). Taken 
together, these results demonstrate that PARG silencing 
is neither synthetic lethal with BRCA1 nor with PTEN 
deficiency.
Discussion
Using cancer cell lines genetically deficient in BRCA1 
and/or PTEN and siRNA-mediated depletions, our 
study shows that PARG deficiency is neither synthetic 
lethal with BRCA1 nor with PTEN deficiency. The fact 
that some cells (MDA-MB-436, HCC1937, UWB1.299) 
display decreased clonogenic survival to PARG deple-
tion cannot be attributed to their BRCA1 and PTEN 
deficiency, since the UWB1.299 cell line complemented 
with BRCA1 (UWB1.299 + BRCA1) displayed the same 
sensitivity to PARG depletion than the parental BRCA1-
deficient UWB1.299 cell line. Moreover, we showed that 
PARG depletion does not sensitize cells simultaneously 
depleted of BRCA1 or PTEN, or both. Although we can-
not exclude that PARG knockdown is incomplete and 
that residual functional PARG could be still sufficient to 
prevent cytotoxicity in BRCA1- and/or PTEN-deficient 
cells, the accumulation of PAR observed in cells trans-
fected with PARG siRNA supports efficient PARG deple-
tion. Specific and cell permeable PARG inhibitors are 
eagerly expected to confirm these findings.
Whereas PARG depletion is not synthetic lethal 
with BRCA1 deficiency, it was shown to be cytotoxic 
to BRCA2-deficient cells [21]. A possible explana-
tion for this different sensitivity between BRCA1 and 
BRCA2-deficient cells could be that BRCA1 acts early 
in the HR process, at the level of the repair pathway 
choice between HR and Non Homologous End Join-
ing (NHEJ), whereas BRCA2 acts at later step of the HR 
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process [39]. In the absence of BRCA1, HR is not initi-
ated and NHEJ can operate to repair the DSB. When HR 
is engaged but halted by the absence of BRCA2, NHEJ 
cannot take over to finish the repair. In light with this, 
it was shown that one of the mechanism of acquired 
resistance of HR-deficient cells towards PARP inhibi-
tors was the mutation of NHEJ factors, such as 53BP1 or 
REV7 [40, 41]. Inactivation of NHEJ leads to the partial 
restoration of homology-directed repair, but this is pos-
sible only in BRCA1-deficient, but not in BRCA2-defi-
cient cells. Whether PARG depletion similarly allows 
bypass of BRCA1 but not BRCA2 function needs further 
investigation. This is however a tempting hypothesis 
that could explain why PARG deficiency is cytotoxic to 
BRCA2-depleted cells [21], but not BRCA1-depleted cells 
(this work).
Nevertheless, the fact that some cells display certain 
sensitivity to PARG depletion supports the idea that tar-
geting PARG expression or activity could be considered 
as an anticancer strategy. PARG depletion was shown 
to affect cell proliferation of LoVo colon cancer cells 
line [42]. Several examples however showed that in the 
absence of exogenous genotoxic stress, PARG depletion 
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Fig. 5 PARG deficiency is not synthetic lethal with PTEN deficiency. a The PTEN‑mutated MDA‑MB‑468 cell line is not sensitive to PARG depletion. 
Clonogenic survival (left panel) of MDA‑MB‑468 cells after siCTL and siPARG transfection. Results are depicted as box plots showing distribution of 
data from 5 individual experiments. Relative cell number 72 h post‑siRNA transfection (right panel) is counted from 5 individual experiments. PARG 
depletion was verified by western blot (middle panel). b Clonogenic survival (left panel) of MDA‑MB‑231 cells after single or combined siRNA‑
mediated depletion of BRCA1, PARG and PTEN. Results are depicted as box plots showing distribution of data from 5 independent experiments. 
Percentage of viable cells relative to siCTL‑transfected cells 72 h post‑transfection (right panel) is counted from 5 individual experiments. BRCA1, 
PARG and PTEN siRNA‑mediated depletions compared to untransfected or siCTL transfected cells were verified by western blot (middle panel). The 
arrow points to BRCA1 signal above a non‑specific band (#). p: 0.01 < * < 0.05; 0.05 < ns, not significant
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as observed in MCF7 cells [21, 43], HeLa cells [8] and 
MDA-MB-231 cells [44]. In contrast, PARG-depletion 
was shown to sensitize tumour cells to genotoxic insult 
caused by ionizing radiations and mild but not severe 
concentrations of alkylating agents or hydrogen peroxide 
[8, 10, 13, 43]. But even the radiosensitization by PARG 
deficiency should not be generalized, since some lung 
tumour cell lines showed no potentialization of radio-
toxicity by PARG depletion [45]. The next challenging 
question will be to determine the molecular signature 
that modulates the sensitivity or resistance to PARG 
invalidation.
Conclusions
Our study shows that although some tumour cells display 
slight sensitivity to PARG deficiency, this sensitivity can-
not be correlated to BRCA1- or PTEN- deficiency. There-
fore, PARG depletion cannot be considered as a strategy 
to kill tumour cells mutated in BRCA1 or PTEN.
Methods
Cell lines
Except when indicated, all cell lines were obtained from 
the American Type Culture Collection (ATCC). MDA-
MB-231 and MDA-MB-436 breast cancer cells were cul-
tivated in RPMI 1640, 10  % foetal bovine serum (FBS, 
Pan Biotech) and 1  % gentamycin (Invitrogen). MDA-
MB-436 have a 5396  +  1G  >A mutation in the splice 
donor site of BRCA1 exon 20 [46] and do not express 
PTEN [23]. The BRCA1 wild type but PTEN-null MDA-
MB-468 basal-like breast cancer cells were cultivated in 
DMEM/F12 HAM (Sigma) supplemented with 2.5  mM 
l-Glutamine (Invitrogen), 10  % FBS and 1  % gentamy-
cin. The non-tumourigenic epithelial MCF10A breast 
cell line expresses wild type BRCA1 and PTEN [38] and 
was cultivated in DMEM/F12 HAM, 5  % horse serum, 
0.01  mg/ml insulin, 20  ng/ml human epidermal growth 
factor, 500  ng/ml hydrocortisone, 100  ng/ml cholera 
toxin and 1 % gentamycin. The osteosarcoma U2OS cell 
line was cultivated in DMEM, 10 % FBS and 1 % genta-
mycin. The PTEN-null and BRCA1-mutated HCC1937 
cell line that carries mutated BRCA1 (5382insC) and are 
homozygous for PTEN deletion [23, 47] was obtained 
from J. Chen (MD Anderson Cancer Center, Houston, 
TX) and cultivated in RPMI 1640, 10 % FBS, 1 % genta-
mycin. The human ovarian cancer cell line UWB1.289 is 
BRCA1-defective (2594delC mutation and deletion of the 
wild type allele) [32]. The UWB1.289 + BRCA1 cell line 
stably expresses full length human BRCA1 [32]. Both cell 
lines were cultivated in 50 % RPMI-1640, 50 % mammary 
epithelial growth medium (Lonza), 3 % FBS and 200 µg/
ml G-418 (for UWB1.289 + BRCA1).
Clonogenic survival assays
Cells were seeded in 6 cm plates and transfected the day 
after with the different siRNA. Two different siRNAs 
targeting PARG were used, from two different provid-
ers: the ON-TARGETplus SMARTpool from Dharma-
con, termed siPARG and the Hs-PARG5-Flexitube from 
Qiagen, termed siPARG5. Their respective non-targeting 
controls were: ON-TARGETplus Non-targeting pool 
from Dharmacon, termed siCTL, and All Stars negative 
control from Qiagen, termed AllNeg. SiRNA targeting 
BRCA1 (siBRCA1) and PTEN (siPTEN) were ON-TAR-
GETplus SMART pool from Dharmacon. Depending on 
the cell line, either JetPRIME (Polyplus) or INTERFERin 
(Polyplus) transfecting agents were used, with a maxi-
mum of 50  nM or 15  nM siRNA, respectively. For co-
transfections, equivalent amounts of the different siRNA 
were mixed and when necessary, completed with siCTL 
to reach the maximum siRNA concentration. Cells were 
trypsinized 72  h post-transfection, seeded in triplicates 
on Petri dishes (10 or 6-cm) and grown for 10–14 days. 
The optimal number of cells seeded and the duration of 
culture were established for each cell line. For survival 
assays performed in the presence of the PARP inhibitor, 
cells were seeded in complete medium supplemented 
with the PARP inhibitor Ku-0058948 [17] at the indi-
cated concentration. Colonies were fixed in 3.7  % for-
maldehyde and stained with 0.1 % crystal violet. Clones 
with more than 50 cells were counted on scanned images 
using Image J, using the maxima intensity detection and 
substraction of background. Determination of mini-
mum clone size was performed under light microscopy. 
Results are represented as the percentage of survival col-
onies within each set of experimental data relative to the 
respective non-targeting control siRNA.
Short term viability assays
Seventy-two hours post-siRNA transfection, cells were 
trypsinized and total viable cells were counted. Relative 
cell number was calculated as the percentage of viable 
cells relative to the number of cells for the respective non-
targeting control siRNA (siCTL or AllNeg), for at least 3 
and up to 11 experiments (indicated in figure legend). 
Short term viability assays was evaluated by a 3-(4,5- 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H- tetrazolium (MTS) assay (CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (Pro-
mega) according to the manufacturer’s instructions. 
After cell counting 72  h post-siRNA transfection, cells 
were plated in triplicate into 96-well tissue culture plates 
and cultivated for up to 96  h. The optimal number of 
cells to be plated was determined for each cell line. Every 
24 h, 20 μl of CellTiter 96® AQueous One Solution Cell 
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Proliferation Reagent (Promega) were added into each 
well of one plate with a multichannel pipette, and after 
1–3  h of incubation at 37  °C in a humidified, 5  % CO2 
atmosphere, the reaction was stopped with 50 μl of a 10 % 
SDS solution. Absorbance was measured at 490 nm using 
a 96-well plate reader (Biochrom Asys UVM340). The 
144 h post-siRNA transfection time point was selected as 
representative of short-term MTS viability, defined as the 
percentage of cell viability relative to the respective non-
targeting control siRNA.
Statistical analyses
Statistical analyses were carried out using R statistical 
packages. For clonogenic assays, short-term MTS viabil-
ity assays and RAD51 foci analyses, data are represented 
as box plot graph where the lower and upper hinges 
represent the 25th and 75th percentile respectively. The 
middle horizontal line represents the median or 50th 
percentile. Whiskers are drawn to the lower and upper 
adjacent values. Far out values are represented by small 
“o”. Significance tests, such as Anova and TukeyHSD 
(honest significant difference, for multiple comparison) 
were performed in R using the dataset used to draw the 
box plot. For cell counting at 72 h post-transfection and 
HR-assays, data are represented as bar plot graphs with 
standard deviation (SD) and significance evaluated using 
Student t test. The number of independent experiments 
is indicated in figure legend. For significance codes p: 0 <‘
***’ <0.001 <‘**’ <0.01 <‘*’ <0.05 <ns (not significant).
Western blot
Cells remaining after the seeding for clonogenic assays 
were pelleted by centrifugation, lysed in 20  mM Tris 
HCl pH 7.5, 400  mM NaCl, 5  mM DTT, 20  % glycerol, 
0.1  % NP40, 1  mM Pefabloc, Protease Inhibitory Cock-
tail (Roche), phosSTOP (Roche), 100  nM Ku-0058948, 
1  µM ADP-HPD (Trevigen) and analysed by western 
blot as previously described [11]. Antibodies used were 
rabbit anti-PAR (1/1000, 4336-BPC-100, Trevigen), anti-
PARG (1/2000, [8]), anti-actin (1/500, A2066, Sigma), 
anti-PTEN (1/2000, ab154812, Abcam) and anti-BRCA1 
(1/5000, 07-434, Millipore) antibodies. Secondary anti-
bodies were either an Alexa Fluor 680 goat anti-rabbit 
(1/30,000, Invitrogen) or a peroxidase-coupled goat anti 
rabbit (1/50,000, Invitrogen), revealed either with Odys-
sey Infrared Imaging System (Li-Cor, Bioscience) or by 
chemiluminescence and autoradiography.
HR‑assay
HR was performed as described in Illuzzi et  al. [11], 
using U2OS cells containing the HR reporter DR-GFP 
and the inducible mCherry-I-SceI-GR (U2OS-DR-GFP- 
mCherry-I-SceI-GR). Cells were transfected with the 
respective siRNA twice, with interval of 48 h, treated for 
2  days with 100  ng/ml of triamcinolone acetonide (TA, 
Sigma) to induce nuclear translocation of the mCherry-
I-SceI-GR before evaluation of the GFP-positive cells out 
of the mCherry-positive cells by flow cytrometry (FACS-
Calibur and Cell Quest software, Becton–Dickinson).
Immunofluorescence
Cells grown on glass coverslips were left untreated or 
treated with etoposide at 10  µM for 1  h, washed twice 
with PBS and incubated in complete medium for 2  h. 
Immunodetection of RAD51 and γH2AX was performed 
as described in Illuzzi et al. [11], using mouse monoclo-
nal anti γH2AX (Ser139) (IgG1, 1/2000, 05-636, Upstate) 
antibody and rabbit polyclonal anti-Rad51 (1/1000, H-93, 
Santa Cruz Biotechnology) antibody. Secondary antibod-
ies were an Alexa Fluor 568 goat anti-mouse IgG and an 
Alexa Fluor 488 goat anti-rabbit IgG (1/2000, Molecular 
Probes, Invitrogen). DNA was counterstained with Dapi.
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